Immuneering Corp (NASDAQ: IMRX)’s stock price has soared by 1972820 in relation to previous closing price of 2.44. Nevertheless, the company has seen a gain of 24.05% in its stock price over the last five trading days. globenewswire.com reported 2025-06-17 that – 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached – – Striking tumor reductions with 39% overall response rate and 81% disease control rate observed as of the data cutoff, including many patients with deepening, durable regressions and multiple examples of individual lesions rendered undetectable – – Markedly favorable tolerability profile observed, demonstrating potential best-in-class profile – – Pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients planned for 2026 – – Company to host conference call at 8:00 a.m. ET today – CAMBRIDGE, Mass.
Is It Worth Investing in Immuneering Corp (NASDAQ: IMRX) Right Now?
Company’s 36-month beta value is 0.05.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IMRX is 25.89M, and currently, short sellers hold a 3.57% ratio of that floaft. The average trading volume of IMRX on June 25, 2025 was 898.78K shares.
IMRX’s Market Performance
IMRX stock saw an increase of 24.05% in the past week, with a monthly gain of 102.76% and a quarterly increase of 68.97%. The volatility ratio for the week is 23.25%, and the volatility levels for the last 30 days are 13.68% for Immuneering Corp (IMRX).. The simple moving average for the past 20 days is 39.88% for IMRX’s stock, with a 57.08% simple moving average for the past 200 days.
Analysts’ Opinion of IMRX
Needham, on the other hand, stated in their research note that they expect to see IMRX reach a price target of $15, previously predicting the price at $20. The rating they have provided for IMRX stocks is “Buy” according to the report published on March 15th, 2024.
IMRX Trading at 79.18% from the 50-Day Moving Average
After a stumble in the market that brought IMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.24% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMRX starting from Hall Brett Matthew, who purchase 7,415 shares at the price of $2.70 back on Jun 20 ’25. After this action, Hall Brett Matthew now owns 353,311 shares of Immuneering Corp, valued at $20,020 using the latest closing price.
Hall Brett Matthew, the CHIEF SCIENTIFIC OFFICER of Immuneering Corp, purchase 6,007 shares at $2.43 during a trade that took place back on Jun 23 ’25, which means that Hall Brett Matthew is holding 359,318 shares at $14,596 based on the most recent closing price.
Stock Fundamentals for IMRX
The total capital return value is set at -1.41. Equity return is now at value -102.48, with -89.10 for asset returns.
Based on Immuneering Corp (IMRX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -13.13.
Currently, EBITDA for the company is -63.69 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.48.
Conclusion
In a nutshell, Immuneering Corp (IMRX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
